PharmacyCodes



RCRA waste number P076 en es it fr

RCRA waste number P076 Brand names, RCRA waste number P076 Analogs

RCRA waste number P076 Brand Names Mixture

  • Aldoril 15 Tab (Hydrochlorothiazide + Methyldopa)
  • Aldoril 25 Tab (Hydrochlorothiazide + Methyldopa)
  • Apo Methazide 15 (Hydrochlorothiazide + Methyldopa)
  • Apo Methazide 25 (Hydrochlorothiazide + Methyldopa)
  • Novo-Doparil 15 Tab (Hydrochlorothiazide + Methyldopa)
  • Novo-Doparil 25 Tab (Hydrochlorothiazide + Methyldopa)
  • Pms-Dopazide 15 Tab (Hydrochlorothiazide + Methyldopa)
  • Pms-Dopazide-25 Tab (Hydrochlorothiazide + Methyldopa)
  • Supres 150 Tab (Chlorothiazide + Methyldopa)
  • Supres 250 Tab (Chlorothiazide + Methyldopa)

RCRA waste number P076 Chemical_Formula

NO

RCRA waste number P076 RX_link

http://www.rxlist.com/cgi/generic/inomax.htm

RCRA waste number P076 fda sheet

RCRA_waste_number_P076 FDA

RCRA waste number P076 msds (material safety sheet)

RCRA_waste_number_P076 MSDS

RCRA waste number P076 Synthesis Reference

No information avaliable

RCRA waste number P076 Molecular Weight

30.0061 g/mol

RCRA waste number P076 Melting Point

-163.6 oC

RCRA waste number P076 H2O Solubility

9.49E+004 mg/L

RCRA waste number P076 State

Liquid

RCRA waste number P076 LogP

0.10

RCRA waste number P076 Dosage Forms

Cream; Drops; Gas; Liquid; Lotion; Ointment; Powder; Tablet

RCRA waste number P076 Indication

For the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure

RCRA waste number P076 Pharmacology

Persistent pulmonary hypertension of the newborn (PPHN) occurs as a primary developmental defect or as a condition secondary to other diseases such as meconium aspiration syndrome (MAS), pneumonia, sepsis, hyaline membrane disease, congenital diaphragmatic hernia (CDH), and pulmonary hypoplasia. In these states, pulmonary vascular resistance (PVR) is high, which results in hypoxemia secondary to right-to-left shunting of blood through the patent ductus arteriosus and foramen ovale. In neonates with PPHN, Nitric oxide improves oxygenation (as indicated by significant increases in PaO2). Nitric oxide appears to increase the partial pressure of arterial oxygen (PaO2) by dilating pulmonary vessels in better entilated areas of the lung, redistributing pulmonary blood flow away from lung regions with low ventilation/perfusion (V/Q) ratios toward regions with normal ratios.

RCRA waste number P076 Absorption

Nitric oxide is absorbed systemically after inhalation.

RCRA waste number P076 side effects and Toxicity

No information avaliable

RCRA waste number P076 Patient Information

No information avaliable

RCRA waste number P076 Organisms Affected

Humans and other mammals